ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035
ImmunityBio announced the issuance of five U.S. patents covering the combination of its IL-15 receptor agonist ANKTIVA with BCG for cancer treatment, with terms extending through at least 2035. The patent portfolio protects the approved ANKTIVA plus BCG product, the specific intravesical dosing regimen, the two-vial commercial kit, and methods of treating non-muscle invasive bladder cancer (NMIBC). This intellectual property position supports the company’s commercial franchise in BCG-unresponsive NMIBC and its advancing clinical trials, including the QUILT-2.005 registrational trial.
Key figures
- Patent count
- 5
- Revenue growth yoy
- 700%
- Patent term expiration
- 2035
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.